Last quote by Michael Nawrath
Jun 22 2017
We can learn a lot about a person if we know what types of things he or she talks about or comments on the most frequently. There are numerous topics with which Michael Nawrath is associated, including Novartis, Actelion, and result. Most recently, Michael Nawrath has been quoted saying: “A positive result of the study would have been welcome to add a little pep to waning Lucentis sales. For the small company Ophthotech this will be much worse than for Novartis, but it's still a negative result.” in the article Novartis eye drug franchise hit by failed Fovista studies. An other article where Michael Nawrath has been quoted is Actelion's ambitious independent-minded CEO will drive up takeover price.
Take our quote verification challenge and find out !
Quotes by Michael Nawrath
Dec 12 2016
A positive result of the study would have been welcome to add a little pep to waning Lucentis sales. For the small company Ophthotech this will be much worse than for Novartis, but it's still a negative result.feedback
Nov 28 2016
Actelion's shares have risen 400 percent based on the strength of the PAH portfolio alone.feedback
Nov 07 2016
Even when the data they are presenting was taken from a sample of only a few patients, the efficacy without the use of any chemotherapy is certainly extraordinarily high.feedback
Oct 01 2016
These court cases are simply the last resort of original drug makers to wring a few more months or a year of exclusivity from their blockbusters.feedback
Check if the quote you read on social networks is authentic
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided